Abstract #2637

Targeted MRI contrast guided drug delivery: Magnevist and doxorubicin encapsulated into liposomes for detection and treatment of glioma

Xiaoli Liu¹, A. B. Madhankumar², Patti A. Miller¹, Becky Webb², James R. Connor², and Qing X. Yang¹

¹Radiology, College of Medicine Penn State University, Hershey, PA, United States, ²Neurosurgery, College of Medicine Penn State University, Hershey, PA, United States

Glioma in its early stage is hard to detect and treat because MRI contrast agent and chemotoxin are not able to cross the blood brain barrier (BBB). The conventional MRI contrast agent such as Magnevist (GD-DTPA) is limited to the cases where the BBB is significantly compromised by the tumor. Present study reports the development of a novel theranostic tool, interleukin-13-liposomes-Magnevist-doxorubicine (IL-13-lip-magnevist-dox) for detection and treatment of glioma. Our results demonstrated that IL-13-lip-magnevist-dox own the potential to specifically target, concomitantly detect and treat glioma in its early stage when BBB is still intact.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.